Modality
mAb
MOA
IL-17i
Target
TIM-3
Pathway
Angiogenesis
BCCPTSD
Development Pipeline
Preclinical
~Jan 2021
→ ~Apr 2022
Phase 1
Jul 2022
→ Feb 2027
Phase 1Current
NCT06751998
1,931 pts·PTSD
2025-02→2025-11·Terminated
NCT05583343
193 pts·BCC
2022-07→2027-02·Terminated
2,124 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-11-085mo agoInterim· PTSD
2027-02-2411mo awayInterim· BCC
Trial Timeline
Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027
P1
Termina…
P1
Termina…
Catalysts
Interim
2025-11-08 · 5mo ago
PTSD
Interim
2027-02-24 · 11mo away
BCC
Terminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06751998 | Phase 1 | PTSD | Terminated | 1931 | FEV1 |
| NCT05583343 | Phase 1 | BCC | Terminated | 193 | HAM-D |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| SNY-2289 | Sanofi | Phase 2/3 | CD38 | |
| Fixainavolisib | Takeda | Preclinical | CDK2 | |
| REG-6699 | Regeneron | Phase 2/3 | TIM-3 | |
| Elrarapivir | Vertex Pharma | NDA/BLA | PRMT5 | |
| Rimaglumide | Biogen | Phase 1/2 | BCL-2 | |
| ARG-3458 | Argenx | Preclinical | RET | |
| Nidasacituzumab | United Therapeutics | Phase 1/2 | TIM-3 | |
| Nidaratamab | Krystal Biotech | Preclinical | RET | |
| Liratinib | Krystal Biotech | NDA/BLA | TIM-3 | |
| Tirarelsin | TG Therapeutics | NDA/BLA | CD19 |